Xeris Pharmaceuticals | XERS - Beneficio Bruto En Ventas

Precio De Mercado
6.37
Cambio Diario
0.25 4.09%
Mensual
17.31%
Anual
58.46%
Q2 Expectativa
5.69




Beneficio Bruto En Ventas Cambio Fecha
Celltrion KRW 626.11B 81.75B 2025-09
Cspc Pharmaceutical CNY 4.01B 329.18M 2025-12
Deva Holding AS TRY 1.32B 235.77M 2023-09
Dianthus Therapeutics USD 284K 112K 2025-12
Divis Laboratories Ltd INR 16.59B 2.05B 2025-12
Eli Lilly USD 14.59B 1.48B 2025-09
Kangmei Pharma CNY 270.29M 20.26M 2025-09
Knight Therapeutics CAD 64.72M 8.91M 2025-12
Laboratorios Farma EUR 105.28M 177.08M 2025-06
Medical Developments International AUD 7.35M 7.37M 2025-06
Nektar Therapeutics USD 21.81M 8.06M 2025-12
Neuren Pharmaceuticals AUD 6.69M 6.37M 2025-06
Organigram Holdings CAD 23.32M 8.52M 2025-12
Pacira USD 142.25M 11.34M 2025-12
Perrigo USD 362.2M 14.9M 2025-12
Pharma Mar EUR 86.7M 53.34M 2025-12
Qiagen NV USD 325.27M 19.53M 2025-12
Sartorius EUR 393.2M 23M 2025-09
Sino Biopharmaceutical CNY 10.5B 2.53B 2024-12
Supernus Pharmaceuticals USD 164.04M 15.23M 2025-12
Tilray USD 57.47M 10.16M 2025-06
Zealand Pharma A/S 68.91M 19.35M 2025-12
Zz Pientze Pharmaceu CNY 296.13M 1.1B 2025-06